Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414726 · ClinicalTrials.gov registry record · Phase 2
Normobaric Oxygen Therapy in Acute Ischemic Stroke Trial
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT00414726: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00414726 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 85 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00414726, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of treating individuals with acute ischemic stroke with normobaric oxygen therapy (NBO, given within 9 hours of symptom onset), to standard medical treatment.
Interventions
- DRUG Room Air
- DRUG NBO (Normobaric Oxygen)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00414726
The ClinicalTrials.gov registry entry for NCT00414726 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Room Air is the first listed.
NCT00414726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00414726 about?
NCT00414726 is a clinical study titled "Normobaric Oxygen Therapy in Acute Ischemic Stroke Trial". The purpose of this study is to compare the safety and efficacy of treating individuals with acute ischemic stroke with normobaric oxygen therapy (NBO, given within 9 hours of symptom onset), to standard medical treatment.
What is the current status of trial NCT00414726?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2007-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00414726?
The interventions under investigation include: Room Air (DRUG), NBO (Normobaric Oxygen) (DRUG).
Who is sponsoring clinical trial NCT00414726?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.